HCW Biologics Inc. (NASDAQ:HCWB) Sees Significant Drop in Short Interest

Posted by Francis Steltz on Jun 11th, 2026

HCW Biologics Inc. (NASDAQ:HCWB – Get Free Report) was the recipient of a large drop in short interest during the month of May. As of May 29th, there was short interest totaling 417,960 shares, a drop of 89.1% from the May 14th total of 3,844,753 shares. Currently, 6.8% of the shares of the company are short sold. Based on an average daily volume of 32,633,321 shares, the days-to-cover ratio is presently 0.0 days.

Insiders Place Their Bets

In other news, Director Scott T. Garrett acquired 177,936 shares of the business’s stock in a transaction that occurred on Friday, May 22nd. The shares were purchased at an average cost of $1.41 per share, for a total transaction of $250,889.76. Following the transaction, the director directly owned 203,441 shares in the company, valued at $286,851.81. This trade represents a 697.65% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 9.10% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On HCW Biologics

An institutional investor recently bought a new position in HCW Biologics stock. Armistice Capital LLC bought a new stake in shares of HCW Biologics Inc. (NASDAQ:HCWB – Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 300,180 shares of the company’s stock, valued at approximately $291,000. Armistice Capital LLC owned 9.15% of HCW Biologics at the end of the most recent quarter. Institutional investors own 2.96% of the company’s stock.

HCW Biologics Stock Up 9.1%

HCW Biologics stock traded up $0.11 during trading hours on Thursday, hitting $1.32. 1,288,419 shares of the company traded hands, compared to its average volume of 36,826,716. The firm has a market cap of $9.45 million, a P/E ratio of -0.14 and a beta of 2.21. The firm’s 50-day simple moving average is $0.96 and its two-hundred day simple moving average is $1.07. HCW Biologics has a 1-year low of $0.25 and a 1-year high of $7.35.

HCW Biologics (NASDAQ:HCWB – Get Free Report) last released its earnings results on Thursday, May 14th. The company reported $0.37 EPS for the quarter, beating the consensus estimate of ($0.44) by $0.81. The firm had revenue of $6.54 million for the quarter, compared to analysts’ expectations of $6.54 million. HCW Biologics had a negative net margin of 34.73% and a negative return on equity of 486.87%.

Wall Street Analyst Weigh In

Several analysts recently weighed in on the stock. Wall Street Zen upgraded shares of HCW Biologics to a “hold” rating in a research report on Saturday, May 23rd. Maxim Group lifted their price objective on shares of HCW Biologics from $2.00 to $5.00 and gave the company a “buy” rating in a research report on Thursday, May 28th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of HCW Biologics in a research report on Tuesday, April 21st. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $5.00.

Check Out Our Latest Analysis on HCW Biologics

HCW Biologics Company Profile

(Get Free Report)

HCW Biologics Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases.